Concentrations of subcutaneously administered belimumab in human breast milk of a woman with systemic lupus erythematosus: a case report

Lupus Sci Med. 2024 Mar 18;11(1):e001167. doi: 10.1136/lupus-2024-001167.

Birgit S Blomjous^{1

2}, Marjon A de Boer^{3

4}, Mirjam M van Weissenbruch^{4

5}, Koen C J Laan⁶, Theo Rispens^{2

7

8}, Alexandre E Voskuyl^{9

2}, Irene E M Bultink^{9

2

4}

¹ Department of Rheumatology and Clinical Immunology, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands b.blomjous@amsterdamumc.nl.
² Amsterdam institute for Infection and Immunity, Amsterdam, The Netherlands.
³ Department of Obstetrics and Gynecology, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
⁴ Amsterdam Reproduction & Development, Amsterdam, The Netherlands.
⁵ Emma Children's hospital Department IC Neonatology, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
⁶ Department of Rheumatology, Dijklander Ziekenhuis, Hoorn, The Netherlands.
⁷ Sanquin Research and Landsteiner Laboratory, Amsterdam UMC location AMC, Amsterdam, The Netherlands.
⁸ Antibodies and Immunogenicity, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
⁹ Department of Rheumatology and Clinical Immunology, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

No abstract available

Keywords: Antibodies; Antirheumatic Agents; Lupus Erythematosus, Systemic; Pharmacokinetics.

Publication types